# Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer

> **NCT05878314** · — · RECRUITING · sponsor: **University Hospital Tuebingen** · enrollment: 504 (estimated)

## Conditions studied

- Hormone Receptor Positive HER-2 Negative Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05878314
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-25
- **Primary completion:** 2027-04
- **Final completion:** 2035-04
- **Target enrollment:** 504 (ESTIMATED)
- **Last updated:** 2026-02-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05878314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05878314, "Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05878314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*